Ipsen is a global biopharmaceutical company focused on the development and commercialization of innovative medicines in three therapeutic areas: Oncology, Rare Diseases, and Neuroscience. The company markets a portfolio of registered medicines, including Somatuline, Cabometyx, Onivyde, Décapeptyl, and Tazverik in Oncology; Bylvay, Iqirvo, and Sohonos in Rare Diseases; and Dysport in Neuroscience. Ipsen serves patients in multiple international markets, with direct commercial presence in various regions. The group maintains long-term partnerships with pharmaceutical and biotechnology companies, including Debiopharm, Exelixis, Servier, Teijin, and Galderma. Founded in 1929 as a family business, the company evolved from the Beaufour Laboratories to its current structure, listing on Euronext in 1995. Ipsen operates research and development centers in the United States, Europe, and China, supporting its pipeline in specialty care and toxin engineering.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - General Homepage ipsen.com
Sector Healthcare IR page ipsen.com/investors
Tags
oncology, rare diseases, neuroscience, specialty care, botulinum toxin, neuroendocrine tumors, liver disease, bone disease, spasticity, biopharmaceuticals, Somatuline, Cabometyx, Onivyde, Décapeptyl, Tazverik, Bylvay, Iqirvo, Sohonos, Dysport, Albireo, Epizyme, Clementia Pharmaceuticals, Merrimack Pharmaceuticals, Exelixis, Debiopharm, Servier, Teijin, Galderma, Blueprint Medicines, GENFIT, ImCheck Therapeutics, Simcere Zaiming, Biomunex, Sutro, Skyhawk, Marengo, Foreseen, Day One Biopharmaceuticals, Kartos Therapeutics, Memo Therapeutics, Fondation Ipsen
Press page ipsen.com/press-releases

Metrics

Valuation  
Market cap € 12.157B
Market cap (USD) $ 13.436B
P/E 23.67
PEG —
P/BV 2.58
P/S 2.67
P/OCF 13.28
P/FCF 14.95
Dividend yield 0.95%
Turnover / mcap —
Returns  
ROE 10.4%
ROI 10.2%
ROIC 10.8%
Profit margin 11.3%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -9.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 20.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score 21.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2011 FY 2010
Revenue 3.929B 3.575B 3.306B 3.156B 2.999B 2.686B 1.16B 1.1B
Net profit 443.5M 345.9M 644.4M 648.6M 646.6M 548M — —
Free cash flow — — — — 813.2M 689.9M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2011 FY 2010
Share price 158.2 111.78 103.83 — — — — —
Price performance 12m 0.42 0.08 — — — — — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) 476M 564M 633M 631M 697M 787M
↳ YoY growth +18.5% +12.1% -0.2% +10.4% +12.9%
↳ 5y CAGR +10.6%
Cash and deposits (EUR) 643M 815M 1.17B 528M 678M 1.53B
Intangible assets (EUR) 1.12B 1.39B 1.59B 2.68B 2.52B 2.29B
Cash flow detail
Operating cash flow (EUR) 771M 909M 971M 866M 916M —
Purchases of property, plant and equipment (EUR) -81.4M -96M — — — —
Purchases of intangible assets (EUR) -59.3M -332M — — — —
Change in receivables (cash effect) (EUR) 56.3M -67.3M -86.8M -1.6M -45.3M -132M
Change in inventories (cash effect) (EUR) -7.1M -500,000 -19.9M -8.9M -20M 22.7M
Change in payables (cash effect) (EUR) 4.5M 83.5M 29.1M 110M 58.8M 41.5M
Dividends paid (cash effect) (EUR) -83.2M -82.9M -99.3M -99.6M -99.6M -116M
Interest paid (cash effect) (EUR) — -21.5M -18.2M -22.6M -8.2M —
Income taxes paid (cash effect) (EUR) — -181M -131M -216M -174M -182M
Share-based compensation (EUR) 22.5M 28.7M 26.5M 30.1M 29.5M 39.3M
Operating cash flow before change in receivables (EUR) 715M 977M 1.06B 868M 961M —
Free cash flow (OCF - PPE - intangibles) (EUR) 631M 482M — — — —
Income detail
Research and development expense (EUR) 406M 428M 445M 619M 687M 754M
↳ 5y CAGR +13.2%
Total comprehensive income (EUR) 466M 712M 697M 594M 461M 307M
Comprehensive income to owners (EUR) 465M 712M 698M 591M 460M 306M
Reported Apr 12, 2022 Apr 6, 2023 Apr 6, 2023 Apr 17, 2024 Apr 7, 2025 Apr 1, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Franchissement e seuil Bull 0 Bear 0 Routine
Franchissement de seuil Bull 0 Bear 0 Routine

Prompts

Ipsen S.A. (ticker IPN), listed in France.

ETFs Holding Ipsen S.A.

ETF Weight in ETF Shares Market value As of
ESIM 1.28% 1,203 $ 231.423K Jul 31, 2026
DTAN 0.63% 765 $ 138.178K Nov 17, 2026
DWMF 0.62% 1,089 $ 210.165K Jun 30, 2026
AVIV 0.34% 38,834 $ 7.126M Nov 16, 2026
RINT 0.18% 1,322 $ 254.975K Jun 30, 2026
SEIE 0.18% 10,350 $ 1.997M Jun 30, 2026
IVSI 0.11% 45 $ 8,679.16 Jun 30, 2026
DFIS 0.10% 32,694 $ 6.042M Nov 12, 2026
AVSD 0.10% 1,996 $ 366.251K Nov 16, 2026
AVDE 0.09% 96,838 $ 17.769M Nov 16, 2026
NBIE 0.08% 1,098 $ 208.015K Aug 31, 2026
DFSI 0.07% 4,646 $ 858.628K Nov 12, 2026
IQSZ 0.07% 603 $ 116.252K Jul 31, 2026
DFIC 0.06% 50,645 $ 9.36M Nov 12, 2026
FENI 0.05% 26,642 $ 5.138M Jun 30, 2026
DFAX 0.04% 29,225 $ 5.401M Nov 12, 2026
JSTC 0.04% 584 $ 107.596K Nov 17, 2026
DXIV 0.04% 509 $ 94.068K Nov 12, 2026
DFAI 0.03% 33,855 $ 6.257M Nov 12, 2026
DIHP 0.03% 10,275 $ 1.899M Nov 12, 2026
DFIV 0.01% 9,865 $ 1.823M Nov 12, 2026